Invention Grant
US08846912B2 Tartrate salts of quinazoline based EGFR inhibitors containing a zinc binding moiety
有权
含有锌结合部分的基于喹唑啉的EGFR抑制剂的酒石酸盐
- Patent Title: Tartrate salts of quinazoline based EGFR inhibitors containing a zinc binding moiety
- Patent Title (中): 含有锌结合部分的基于喹唑啉的EGFR抑制剂的酒石酸盐
-
Application No.: US13900165Application Date: 2013-05-22
-
Publication No.: US08846912B2Publication Date: 2014-09-30
- Inventor: Xiong Cai , Changgeng Qian , Haixiao Zhai
- Applicant: Curis, Inc.
- Applicant Address: US MA Lexington
- Assignee: Curis, Inc.
- Current Assignee: Curis, Inc.
- Current Assignee Address: US MA Lexington
- Agency: Elmore Patent Law Group, P.C.
- Agent Edgar W. Harlan; Carolyn S. Elmore, Esq.
- Main IPC: C07D239/94
- IPC: C07D239/94 ; C07C59/255 ; C07D409/12 ; C07C259/04 ; C07D403/12 ; C07D405/12 ; C07D401/12
Abstract:
The present invention relates to tartrate salts of quinazoline containing zinc-binding moiety based derivatives of Formula II, below: These compounds are inhibitors of epidermal growth factor receptor tyrosine kinase (EGFR-TK) and may further act as HDAC inhibitors. The invention further relates to the use of these tartrate salts in the treatment of EGFR-TK related diseases and disorders such as cancer.
Public/Granted literature
- US20130338167A1 TARTRATE SALTS OF QUINAZOLINE BASED EGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY Public/Granted day:2013-12-19
Information query
